Quick Answer
RESMED INC reported Total Revenue of $5.15 billion for fiscal year 2025.
RESMED INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.15B +9.8% |
$4.69B +10.9% |
$4.22B +18.0% |
$3.58B +11.9% |
$3.20B +8.1% |
$2.96B +13.4% |
| Revenue (ASC 606) | $5.15B +9.8% |
$4.69B +10.9% |
$4.22B +18.0% |
$3.58B +11.9% |
$3.20B +8.1% |
$2.96B +13.4% |
| Net Income | $1.40B +37.2% |
$1.02B +13.7% |
$897.56M +15.2% |
$779.44M +64.3% |
$474.50M -23.7% |
$621.67M +53.7% |
| Diluted EPS | $9.51 +37.4% |
$6.92 +13.6% |
$6.09 +14.9% |
$5.30 +63.6% |
$3.24 -24.1% |
$4.27 +52.5% |
| Total Assets | $8.17B +18.9% |
$6.87B +1.8% |
$6.75B +32.5% |
$5.10B +7.8% |
$4.73B +3.1% |
$4.59B +11.7% |
| Cash and Equivalents | $1.21B +407.4% |
$238.36M +4.6% |
$227.89M -16.7% |
$273.71M -7.3% |
$295.28M -36.2% |
$463.16M +214.8% |
| Long-Term Debt | $658.39M -5.6% |
$697.31M -51.3% |
$1.43B +87.0% |
$765.33M +19.0% |
$643.35M -44.7% |
$1.16B -7.5% |
| Stockholders Equity | $5.97B +22.7% |
$4.86B +17.8% |
$4.13B +22.9% |
$3.36B +16.5% |
$2.89B +15.6% |
$2.50B +20.5% |
| R&D Expense | $331.28M +7.7% |
$307.52M +6.9% |
$287.64M +13.4% |
$253.57M +12.6% |
$225.28M +11.6% |
$201.95M +11.8% |
| Operating Income | $1.69B +27.7% |
$1.32B +16.6% |
$1.13B +13.2% |
$1.00B +10.7% |
$903.68M +11.6% |
$809.66M +39.8% |
| Gross Profit | $3.05B +15.1% |
$2.66B +12.7% |
$2.36B +16.4% |
$2.02B +10.1% |
$1.84B +7.1% |
$1.72B +15.0% |
| Shares Outstanding | 146.39M -0.4% |
146.90M -0.1% |
147.06M +0.4% |
146.41M +0.5% |
145.65M +0.5% |
144.89M +0.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $1.42B | +11.0% | +6.5% |
| Revenue (ASC 606) | December 31, 2025 | $1.42B | +11.0% | +6.5% |
| Net Income | December 31, 2025 | $392.59M | +13.9% | +12.6% |
| Diluted EPS | December 31, 2025 | $2.68 | +14.5% | +13.1% |
| Total Assets | December 31, 2025 | $8.50B | +19.1% | +2.3% |
| Cash and Equivalents | December 31, 2025 | $1.42B | +171.5% | +2.4% |
| Long-Term Debt | December 31, 2025 | $403.92M | -39.1% | -1.2% |
| Stockholders Equity | December 31, 2025 | $6.32B | +20.3% | +3.3% |
| R&D Expense | December 31, 2025 | $90.97M | +11.8% | +4.2% |
| Operating Income | December 31, 2025 | $491.66M | +17.8% | +10.1% |
| Gross Profit | December 31, 2025 | $878.72M | +17.0% | +7.1% |
| Shares Outstanding | December 31, 2025 | 145.66M | -0.8% | -0.2% |
- RESMED INC reported Total Revenue of $5.15 billion for fiscal year 2025.
- RESMED INC showed an increase of +9.8% in Total Revenue compared to the prior fiscal year.
- RESMED INC reported Revenue (ASC 606) of $5.15 billion for fiscal year 2025.
- RESMED INC showed an increase of +9.8% in Revenue (ASC 606) compared to the prior fiscal year.
- RESMED INC reported Net Income of $1.40 billion for fiscal year 2025.
- RESMED INC showed an increase of +37.2% in Net Income compared to the prior fiscal year.
- RESMED INC reported Diluted EPS of $9.51 per share for fiscal year 2025.
- RESMED INC showed an increase of +37.4% in Diluted EPS compared to the prior fiscal year.
- RESMED INC reported Total Assets of $8.17 billion for fiscal year 2025.
- RESMED INC showed an increase of +18.9% in Total Assets compared to the prior fiscal year.
- RESMED INC reported Cash and Equivalents of $1.21 billion for fiscal year 2025.
- RESMED INC showed an increase of +407.4% in Cash and Equivalents compared to the prior fiscal year.
- RESMED INC reported Long-Term Debt of $658.39 million for fiscal year 2025.
- RESMED INC showed a decrease of -5.6% in Long-Term Debt compared to the prior fiscal year.
- RESMED INC reported Stockholders Equity of $5.97 billion for fiscal year 2025.
- RESMED INC showed an increase of +22.7% in Stockholders Equity compared to the prior fiscal year.
- RESMED INC reported R&D Expense of $331.28 million for fiscal year 2025.
- RESMED INC showed an increase of +7.7% in R&D Expense compared to the prior fiscal year.
- RESMED INC reported Operating Income of $1.69 billion for fiscal year 2025.
- RESMED INC showed an increase of +27.7% in Operating Income compared to the prior fiscal year.
- RESMED INC reported Gross Profit of $3.05 billion for fiscal year 2025.
- RESMED INC showed an increase of +15.1% in Gross Profit compared to the prior fiscal year.
- RESMED INC reported Shares Outstanding of 146.39 million shares for fiscal year 2025.
- RESMED INC showed a decrease of -0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: